The effect of taurine on chronic heart failure: actions of taurine against catecholamine and angiotensin II
- 975 Downloads
Taurine, a ubiquitous endogenous sulfur-containing amino acid, possesses numerous pharmacological and physiological actions, including antioxidant activity, modulation of calcium homeostasis and antiapoptotic effects. There is mounting evidence supporting the utility of taurine as a pharmacological agent against heart disease, including chronic heart failure (CHF). In the past decade, angiotensin II blockade and β-adrenergic inhibition have served as the mainstay in the treatment of CHF. Both groups of pharmaceutical agents decrease mortality and improve the quality of life, a testament to the critical role of the sympathetic nervous system and the renin--angiotensin system in the development of CHF. Taurine has also attracted attention because it has beneficial actions in CHF, in part by its demonstrated inhibition of the harmful actions of the neurohumoral factors. In this review, we summarize the beneficial actions of taurine in CHF, focusing on its antagonism of the catecholamines and angiotensin II.
KeywordsChronic heart failure Angiotensin II Catecholamine Taurine
This review work is supported from Grants-in-Aid from the Ministry of Health, Labor and Welfare and from the Ministry of Education, Science, Sports and Culture of Japan. This work is also supported by a research grant from Taisho Pharmaceutical Co. Ltd. (Japan).
- Azuma J, Katsume H, Kagisgima T, Furukawa K, Awata N, Ishiyama T, Yamagami T, Ishikawa H, Iwata H, Kishimoto S et al (1989) Clinical evaluation of taurine in congestive heart failure—a double-blind comparative study using CoQ10 as a control drug. In: Iwata H, Lombardini JB, Segawa T (eds) Taurine and the heart. Kluwer Academic Publishers, Boston, pp 75–97CrossRefGoogle Scholar
- Gomes da Silva AQ, Xavier CH, Campagnole-Santos MJ, Caligiorne SM, Baltatu OC, Bader M, Santos RA, Fontes MA (2012) Cardiovascular responses evoked by activation or blockade of GABA(A) receptors in the hypothalamic PVN are attenuated in transgenic rats with low brain angiotensinogen. Brain Res 1448:101–110PubMedCrossRefGoogle Scholar
- Ito T, Azuma J (2012) Taurine depletion-related cardiomyopathy in animals. In: Veselka J (ed) Cardiomyopathies—from basic research to clinical management. doi: 10.5772/30023. ISBN 978-953-307-834-2
- Jeejeebhoy F, Keith M, Freeman M, Barr A, McCall M, Kurian R, Mazer D, Errett L (2002) Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 143:1092–1100PubMedCrossRefGoogle Scholar
- Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, Dalton ND, Peterson KL, Chen J, Bers D et al (2009) Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest 119:1230–1240PubMedCentralPubMedCrossRefGoogle Scholar
- Marcinkiewicz J, Kontny E (2012) Taurine and inflammatory diseases. Amino acids [Epub ahead of print]Google Scholar
- Novotny MJ, Hogan PM, Flannigan G (1994) Echocardiographic evidence for myocardial failure induced by taurine deficiency in domestic cats. Can J Vet Res-Revue Canadienne De Recherche Veterinaire 58:6–12Google Scholar
- Zulli A, Lau E, Wijaya BP, Jin X, Sutarga K, Schwartz GD, Learmont J, Wookey PJ, Zinellu A, Carru C et al (2009) High dietary taurine reduces apoptosis and atherosclerosis in the left main coronary artery: association with reduced CCAAT/enhancer binding protein homologous protein and total plasma homocysteine but not lipidemia. Hypertension 53:1017–1022PubMedCrossRefGoogle Scholar